ArticlemBio2024
Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against
Abstract read
In one paragraph
Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Protein Spatial Structure Meets Artificial Intelligence: Revolutionizing Drug Synergy-Antagonism in Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Pooled it
- Chemoproteomic Elucidation of β-Lactam Drug Targets inACS infectious diseases · 2026Article
- Synergistic activity of dual β-lactams againstMicrobiology spectrum · 2026Article
- The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates.The Journal of antimicrobial chemotherapy · 2026Article
- Efficacy of a reduced-drug burden quadruple therapy with vonoprazan, cefuroxime, minocycline, and bismuth forFrontiers in medicine · 2026Article
- Oral β-lactam combinations are effectiveMicrobiology spectrum · 2025Article
- Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect againstMicrobiology spectrum · 2025Article
- Successful treatment of macrolide-resistantASM case reports · 2025Article
- Article
- Novel C5α-substituted carbapenems enhanceAntimicrobial agents and chemotherapy · 2025Article
- Review
- Toward a Bactericidal Oral Drug Combination for the Treatment ofACS infectious diseases · 2025Article
- Durlobactam in combination with β-lactams to combatAntimicrobial agents and chemotherapy · 2025Article
- Activity of combinations of bactericidal and bacteriostatic compounds inFrontiers in microbiology · 2025Review
- The Advance and Clinical Practice on Lung Disease Caused byInfection and drug resistance · 2025Article
- Toward better cures forClinical microbiology reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Khalid M Dousa *Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0003-3272-7231
Eunjeong Shin *Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0009-0006-2472-3264
Sebastian G KurzDepartment of Medicine, University of Tübingen, Tübingen, Germany.
Mark PlummerYale Center for Molecular Discovery, Yale University, New Haven, Connecticut, USA.
Mary NantongoDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0003-0137-6248
Christopher R BethelLouis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Magdalena A TaracilaLouis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0003-3272-7231
David C NguyenDepartment of Pediatrics, Division of Pediatric Infectious Diseases and Department of Internal Medicine, Division of Infectious Diseases, Rush Medical College, Chicago, Illinois, USA.
Barry N KreiswithCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Charles L DaleyDivision of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado, USA.
Kenneth E RemyDepartment of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Steven M HollandLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Robert A BonomoLouis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-3299-894X
Funding
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MMicrobiology and Immunology Training for HIV and HIV-Related Research in Uganda (MITHU)D43TW010319 · FIC · CASE WESTERN RESERVE UNIVERSITY · PI BOOM, W. HENRY, JOLOBA, MOSES LUTAAKOME · 2016 to 2025
$3.1MThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974FIC NIH HHS D43 TW010319HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI100560, R01AI063517, R01AI072219NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560U.S. Department of Veterans Affairs (VA) 1I01BX001974
Abstract
IMPORTANCE: Treating infections from
Indexed as
Anti-Bacterial AgentsCefuroximeDrug SynergismMicrobial Sensitivity TestsMycobacterium abscessusbeta-Lactamase InhibitorsHumansMolecular Docking SimulationMycobacterium Infections, NontuberculousProhibitinsAnti-Bacterial Agentsbeta-Lactamase InhibitorsCefuroximePHB2 protein, humanProhibitinsdual β-lactamsMycobacterium abscessusoral carbapenemsulopenem
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.